Table of Content


Chapter 1 Methodology & Scope
1.1 Market definitions
1.2 Base estimates and working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Fabry disease treatment industry 360 degree synopsis, 2017 - 2030 (USD Million)
2.1.1 Business trends
2.1.2 Treatment type trends
2.1.3 Regional trends
Chapter 3 Fabry Disease Treatment Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising cases of Fabry disease across the globe
3.3.1.2 Growing awareness among specialist and physicians
3.3.1.3 Advancements in Fabry disease treatment therapies
3.3.1.4 Rising health awareness and demand for early-stage diagnosis
3.3.2 Industry pitfalls & challenges
3.3.2.1 High treatment cost
3.4 Growth potential analysis
3.4.1 By treatment
3.5 COVID- 19 impact analysis
3.6 Future market trends
3.7 Technology landscape
3.8 Pricing analysis
3.9 Brand analysis
3.10 Gap analysis
3.11 Product pipeline analysis
3.12 Reimbursement scenario
3.13 Regulatory landscape
3.13.1 U.S.
3.13.2 Europe
3.14 Porter’s Analysis
3.15 Competitive landscape, 2021
3.15.1 Company matrix analysis, 2021
3.15.2 Company market share analysis, 2021
3.15.3 Global
3.15.4 North America
3.15.5 Europe
3.15.6 Asia Pacific
3.15.7 Latin America
3.15.8 MEA
3.16 PESTLE Analysis
Chapter 4 Fabry Disease Treatment Market, By Treatment Type
4.1 Key segment trends
4.2 Enzyme Replacement Therapy (ERT)
4.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.2 By Drug Type
4.2.2.1 Agalidase Alpa
4.2.2.1.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.2.2 Agalidase Beta
4.2.2.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.3 By End-use
4.2.3.1 Physician office
4.2.3.1.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.3.2 Home settings
4.2.3.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Chaperone Therapy
4.3.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 5 Fabry Disease Treatment Market, By Region
5.1 Key regional trends
5.2 North America
5.2.1 Market size, by country, 2017 - 2030 (USD Million)
5.2.2 Market size, by treatment type, 2017 - 2030 (USD Million)
5.2.2.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.2.2.2 Market size, by end-use, 2017 -2030 (USD Million)
5.2.3 U.S.
5.2.3.1 Market size, by treatment type, 2017-2030 (USD Million)
5.2.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.2.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.2.4 Canada
5.2.4.1 Market size, by treatment type, 2017-2030 (USD Million)
5.2.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.2.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3 Europe
5.3.1 Market size, by country, 2017 - 2030 (USD Million)
5.3.2 Market size, by treatment type, 2017 - 2030 (USD Million)
5.3.2.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.2.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.3 Germany
5.3.3.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.4 UK
5.3.4.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.5 France
5.3.5.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.6 Spain
5.3.6.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.6.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.6.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.7 Italy
5.3.7.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.7.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.7.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4 Asia Pacific
5.4.1 Market size, by country, 2017 - 2030 (USD Million)
5.4.2 Market size, by treatment type, 2017 - 2030 (USD Million)
5.4.2.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.2.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.3 Japan
5.4.3.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.4 China
5.4.4.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.5 India
5.4.5.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.6 Australia
5.4.6.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.6.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.6.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.7 South Korea
5.4.7.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.7.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.7.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.5 ROW
5.5.1 Market size, by treatment type, 2017 - 2030 (USD Million)
5.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
Chapter 6 Company Profiles
6.1 Competitive dashboard, 2021
6.2 Sanofi
6.2.1 Business Overview
6.2.2 Financial Data
6.2.3 Product Landscape
6.2.4 Strategic Outlook
6.2.5 SWOT Analysis
6.3 Takeda
6.3.1 Business Overview
6.3.2 Financial Data
6.3.3 Product Landscape
6.3.4 Strategic Outlook
6.3.5 SWOT Analysis
6.4 Amicus Therapeutics
6.4.1 Business Overview
6.4.2 Financial Data
6.4.3 Product Landscape
6.4.4 Strategic Outlook
6.4.5 SWOT Analysis
6.5 ISU Abaxis
6.5.1 Business Overview
6.5.2 Financial Data
6.5.3 Product Landscape
6.5.4 Strategic Outlook
6.5.5 SWOT Analysis
6.6 JCR Pharmaceuticals Co Ltd.
6.6.1 Business Overview
6.6.2 Financial Data
6.6.3 Product Landscape
6.6.4 Strategic Outlook
6.6.5 SWOT Analysis



List of Tables

Data Tables
TABLE 1. Global Fabry disease treatment market, 2017 - 2021 (USD Million)
TABLE 2. Global Fabry disease treatment market, 2022 - 2030 (USD Million)
TABLE 3. Global Fabry disease treatment market, by treatment type, 2017 - 2021 (USD Million)
TABLE 4. Global Fabry disease treatment market, by treatment type, 2022 - 2030 (USD Million)
TABLE 5. Global Fabry disease treatment market, by region, 2017 - 2021 (USD Million)
TABLE 6. Global Fabry disease treatment market, by region, 2022 - 2030 (USD Million)
TABLE 7. Industry impact forces
TABLE 8. Enzyme replacement therapy (ERT) market, by region, 2017 - 2021, (USD Million)
TABLE 9. Enzyme replacement therapy (ERT) market, by region, 2022 - 2030, (USD Million)
TABLE 10. Agalidase Alpha market, by region, 2017 - 2021, (USD Million)
TABLE 11. Agalidase Alpha market, by region, 2022 - 2030, (USD Million)
TABLE 12. Agalidase Beta market, by region, 2017 - 2021, (USD Million)
TABLE 13. Agalidase Beta market, by region, 2022 - 2030, (USD Million)
TABLE 14. Physician office market, by region, 2017 -2021 (USD Million)
TABLE 15. Physician office market, by region, 2022 -2030 (USD Million)
TABLE 16. End-use market, by region, 2017 -2021 (USD Million)
TABLE 17. End-use market, by region, 2017 -2021 (USD Million)
TABLE 18. Chaperone therapy market, by region, 2017 - 2021, (USD Million)
TABLE 19. Chaperone therapy market, by region, 2022 - 2030, (USD Million)
TABLE 20. North America Fabry disease treatment market, by country, 2017-2021, (USD Million)
TABLE 21. North America Fabry disease treatment market, by country, 2022-2030, (USD Million)
TABLE 22. North America Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 23. North America Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 24. North America enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 25. North America enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 26. North America enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 27. North America enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 28. U.S. Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 29. U.S. Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 30. U.S. enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 31. U.S. enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 32. U.S. enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 33. U.S. enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 34. Canada Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 35. Canada Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 36. Canada enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 37. Canada enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 38. Canada enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 39. Canada enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 40. Europe Fabry disease treatment market, by country, 2017-2021, (USD Million)
TABLE 41. Europe Fabry disease treatment market, by country, 2022-2030, (USD Million)
TABLE 42. Europe Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 43. Europe Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 44. Europe enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 45. Europe enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 46. Europe enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 47. Europe enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 48. Germany Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 49. Germany Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 50. Germany enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 51. Germany enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 52. Germany enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 53. Germany enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 54. UK Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 55. UK Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 56. UK enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 57. UK enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 58. UK enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 59. UK enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 60. France Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 61. France Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 62. France enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 63. France enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 64. France enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 65. France enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 66. Spain Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 67. Spain Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 68. Spain enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 69. Spain enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 70. Spain enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 71. Spain enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 72. Italy Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 73. Italy Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 74. Italy enzyme replacement therapy (ERT) market, by drug type, 2017 -2021, (USD Million)
TABLE 75. Italy enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 76. Italy enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 77. Italy enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 78. Asia Pacific Fabry disease treatment market, by country, 2017-2021, (USD Million)
TABLE 79. Asia Pacific Fabry disease treatment market, by country, 2022-2030, (USD Million)
TABLE 80. Asia Pacific Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 81. Asia Pacific Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 82. Asia Pacific enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 83. Asia Pacific enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 84. Asia Pacific enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 85. Asia Pacific enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 86. Japan Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 87. Japan Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 88. Japan enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 89. Japan enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 90. Japan enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 91. Japan enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 92. China Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 93. China Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 94. China enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 95. China enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 96. China enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 97. China enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 98. India Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 99. India Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 100. India enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 101. India enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 102. India enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 103. India enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 104. Australia Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 105. Australia Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 106. Australia enzyme replacement therapy (ERT) market, by drug type, 2017-2021, (USD Million)
TABLE 107. Australia enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 108. Australia enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 109. Australia enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 110. South Korea Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 111. South Korea Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 112. South Korea enzyme replacement therapy (ERT) market, by drug type, 2017 -2021, (USD Million)
TABLE 113. South Korea enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 114. South Korea enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 115. South Korea enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)
TABLE 116. ROW Fabry disease treatment market, by treatment type, 2017-2021, (USD Million)
TABLE 117. ROW Fabry disease treatment market, by treatment type, 2022-2030, (USD Million)
TABLE 118. ROW enzyme replacement therapy (ERT) market, by drug type, 2017 -2021, (USD Million)
TABLE 119. ROW enzyme replacement therapy (ERT) market, by drug type, 2022-2030, (USD Million)
TABLE 120. ROW enzyme replacement therapy (ERT) market, by end-use, 2017-2021, (USD Million)
TABLE 121. ROW enzyme replacement therapy (ERT) market, by end-use, 2022-2030, (USD Million)

Charts & Figures
FIG. 1 Top-down approach
FIG. 2 Data validation
FIG. 3 Fabry disease treatment industry 360 degree synopsis, 2017 - 2030
FIG. 4 Industry segmentation
FIG. 5 Global Fabry disease treatment market, by region, 2017 - 2030 (USD Million)
FIG. 6 Growth potential analysis, by treatment type
FIG. 7 Porter’s analysis
FIG. 8 Company matrix analysis, 2021
FIG. 9 Global company share analysis, 2021
FIG. 10 North America market share analysis, 2021
FIG. 11 Europe market share analysis, 2021
FIG. 12 Asia Pacific market share analysis, 2021
FIG. 13 ROW market share analysis, 2021
FIG. 14 PESTEL analysis
FIG. 15 Key segment trends, by treatment type
FIG. 16 Key regional trends
FIG. 17 Strategy dashboard, 2021